Patent ID: 9526774
Filing Date: 2016-12-27
CPC Classification: A61K,C07K,C12N,C12Y

Claim Text:
1. A pharmaceutical composition comprising a mixture of vectors for generating antibody response against methicillin resistant Staphylococcus aureus (MRSA) in an individual, each of said vectors comprising one of four transcription units each encoding a different fusion protein, each of said four fusion proteins comprising (i) a different one of SEQ ID NOS 1-4, (ii) an extracellular domain of a secretable CD40 ligand, and (iii) a separate linker connecting each of the SEQ ID NOS 1-4 to an amino terminal end of the extracellular domain of the CD40 ligand, wherein said composition has the ability to promote antibody response for blocking the virulence of one or more virulence antigenic factors of MRSA.